Difference between revisions of "Part:BBa K4361302"
Line 27: | Line 27: | ||
<html> | <html> | ||
<h3>Usage and Biology</h3> | <h3>Usage and Biology</h3> | ||
− | The set of BlcR mutants (</html>[[Part:BBa_K4361300]] through [[Part:BBa_K4361319]]<html>) were expressed in a PURE system in the presence of GreenLys (fluorescent Cy2-labeled lysine). Samples were then run on an SDS PAGE gel (<b>Figure 1.</b>) to determine whether or not the protein was produced. For this mutant (<u>lane 3</u>), a band | + | The set of BlcR mutants (</html>[[Part:BBa_K4361300]] through [[Part:BBa_K4361319]]<html>) were expressed in a PURE system in the presence of GreenLys (fluorescent Cy2-labeled lysine). Samples were then run on an SDS PAGE gel (<b>Figure 1.</b>) to determine whether or not the protein was produced. For this mutant (<u>lane 3</u>), a protein band corresponding to the BlcR monomer is visible. Concluding that the production in an E. coli cell-free system was successful for this mutant. |
<figure> | <figure> | ||
<a href="https://static.igem.wiki/teams/4361/wiki/results/figure-7-pure/figure-7-pure-3.png"><img src="https://static.igem.wiki/teams/4361/wiki/results/figure-7-pure/figure-7-pure-3.png" style="width:600px;margin-left:125px"></a> | <a href="https://static.igem.wiki/teams/4361/wiki/results/figure-7-pure/figure-7-pure-3.png"><img src="https://static.igem.wiki/teams/4361/wiki/results/figure-7-pure/figure-7-pure-3.png" style="width:600px;margin-left:125px"></a> | ||
− | <figcaption> <b>Figure 1.</b> SDS PAGE | + | <figcaption> <b>Figure 1.</b> SDS PAGE showing the translation products of 20 different plasmids coding for BlcR mutants. PURE reaction solution was supplemented with GreenLys and the synthesized proteins were imaged with Typhoon using a 488-nm laser. C: negative control with no plasmid. WT: positive control with expressed wildtype BlcR. 3: A40V mutant</figcaption> |
</figure> | </figure> | ||
Revision as of 15:41, 12 October 2022
BlcR A40V
A mutant of the BlcR protein, created through site-directed mutagenesis with primers R4 (Part:BBa_K4361204) and F4.1 A40V (Part:BBa_K4361205). For this mutant, the alanine in position 40 has been changed to valine by mutating the GCG codon to GTG.
This mutant also contains the following nucleotide mutations outside of the targeted site:
- G 474 > T, silent mutation
- T 529 > C, resulting in substitution F177L
- G 606 > T, silent mutation
- T 618 > A, silent mutation
- G 648 > T, resulting in substitution E216D
- T 681 > A, resulting in substitution E227D
- G 742 > A, resulting in substitution E248A
- A 745 > C, resulting in substitution K249Q
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12INCOMPATIBLE WITH RFC[12]Illegal NheI site found at 694
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 78
- 1000INCOMPATIBLE WITH RFC[1000]Illegal SapI.rc site found at 589
Usage and Biology
The set of BlcR mutants (Part:BBa_K4361300 through Part:BBa_K4361319) were expressed in a PURE system in the presence of GreenLys (fluorescent Cy2-labeled lysine). Samples were then run on an SDS PAGE gel (Figure 1.) to determine whether or not the protein was produced. For this mutant (lane 3), a protein band corresponding to the BlcR monomer is visible. Concluding that the production in an E. coli cell-free system was successful for this mutant.